# Icotinib Versus Placebo as Adjuvant Therapy in EGFR-mutant Lung Adenocarcinoma

> **NCT02125240** · PHASE3 · UNKNOWN · sponsor: **Betta Pharmaceuticals Co., Ltd.** · enrollment: 124 (estimated)

## Conditions studied

- EGFR Positive Non-small Cell Lung Cancer
- Adenocarcinoma

## Interventions

- **DRUG:** Icotinib
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT02125240
- **Lead sponsor:** Betta Pharmaceuticals Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2014-09
- **Primary completion:** 2018-12
- **Final completion:** 2021-07
- **Target enrollment:** 124 (ESTIMATED)
- **Last updated:** 2018-07-16


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02125240

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02125240, "Icotinib Versus Placebo as Adjuvant Therapy in EGFR-mutant Lung Adenocarcinoma". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT02125240. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*